Recent Updates
Recently added Catalysts
PRCT Positive Sentiment Score: 75/100

PROCEPT BioRobotics to Present at the 44th Annual TD Cowen Health Care Conference in Boston

Key Takeaway: PROCEPT BioRobotics announced its participation at the 44th Annual TD Cowen Health Care Conference in Boston, where management will present on March 5. The presentation is expected to discuss their innovative AquaBeam Robotic System, aimed at improving patient care in urology, particularly for benign prostatic hyperplasia (BPH). The company emphasizes its commitment to advancing surgical techniques through well-supported clinical evidence. The event will include a live webcast available for replay afterward.

Market Sentiment Analysis

POSITIVE FACTORS

  • Management is sharing insights at a prestigious health care conference.
  • The presentation could enhance visibility and investor interest.
  • The company has a solid foundation with robust clinical evidence for its technology.

Full Press Release Details

SAN JOSE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 44th Annual TD Cowen Health Care Conference in Boston. Management is scheduled to present on Tuesday, March 5 at 12:50 p.m. Eastern Time. A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
VP, Investor Relations and Business Operations

Frequently Asked Questions

When is PROCEPT BioRobotics presenting at the TD Cowen Conference?

PROCEPT BioRobotics will present on Tuesday, March 5, at 12:50 p.m. ET.

Where can I watch the PROCEPT BioRobotics conference presentation?

The presentation can be accessed via a live webcast on their Investors page.

What is PROCEPT BioRobotics focused on?

PROCEPT BioRobotics specializes in surgical robotics for advancing urology patient care.

What condition does the AquaBeam Robotic System primarily treat?

The AquaBeam system primarily treats benign prostatic hyperplasia (BPH).

How many clinical studies support Aquablation therapy?

Aquablation therapy is supported by nine clinical studies and over 150 publications.

Last updated: Feb 12, 2024